U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH).

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101.

Nitroglycerin, a minuscule molecule drug concocted by Merck, made its debut in the pharmaceutical market in 1983.

Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024.

Recently, AstraZeneca reported in detail the discovery process of the RXFP1 agonist AZD5462, currently in Phase II clinical trials, in two consecutive articles published in the top-tier journal JMC (Journal of Medicinal Chemistry).

Chugai Pharmaceutical revealed Phase III LUMINESCE trial results for their drug Enspryng (satralizumab).

Atomoxetine, a diminutive molecule drug concocted by Eli Lilly, procured its inaugural medical approval in 2002.

FDA Approves NMD Pharma's IND Application for Phase 2b Trial of NMD670 in US Myasthenia Gravis Population.

On March 18th, Bristol Myers Squibb (BMS) finalized its acquisition of Karuna Therapeutics, enhancing its neuroscience investments. Karuna has stopped NASDAQ trading and is now fully owned by BMS.

Molecure S.A. is dedicated to finding new treatments for diseases once thought incurable, focusing on small-molecule and mRNA-based drugs. The company is now conducting a Phase II trial of their drug OATD-01 for active pulmonary sarcoidosis.

Midodrine, a diminutive molecule of therapeutic nature, exhibits its therapeutic effect through its agonistic action upon the α-adrenergic receptor.

Mission Therapeutics has initiated a pivotal study on MTX325, which could potentially alter the progression of Parkinson’s Disease.